Tag: Cancer Drugs

Many patients who are diagnosed with cancer will require treatment with cancer drugs. Treatment with cancer drugs is usually led by a doctor known as a medical oncologist.

EC Approved Lynparza as 1st-Line Maintenance Treatment for BRCA-Mutated Ovarian Cancer

astrazeneca
AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced that the European Commission (EC) has approved Lynparza (olaparib) as a 1st-line...

Five-Year Survival Data for Blincyto Unveiled by Amgen

amgen
Amgen has revealed “compelling” long-term survival data for its acute lymphoblastic leukemia (ALL) drug Blincyto (blinatumomab). The five-year overall survival (OS) analysis – based on data from th...

GC Pharma Established Cell Therapy Development Company

GC Pharma and affiliate GC LabCell said Thursday they have jointly established a cell therapy development company called Artiva Biotherapeutics. Artiva Biotherapeutics was launched in March in San ...

Bayer and Two Chinese Companies to Evaluate PD-L1 in Combination with Regorafenib

CStone Pharmaceuticals announced that the company has entered into a global clinical collaboration with China focus with Bayer HealthCare LLC to evaluate the safety, tolerability, pharmacokinetics (PK...

Taiho Will Commercialize Two Pharmaceuticals’ Drug Candidates in North America

otsuka
Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Taiho Pharmaceutical Co., Ltd. announce that commercialization rights in the U.S. and Canada for anti-cancer drug candidates guadecitabine and ASTX727 will...

New Russian Gastric Cancer Treatment Passed Pre-Clinical Trials

Our colleagues have brilliantly finished pre-clinical trials, although this process was not easy. The company has scored significant results, won high marks from experts and secured sufficient funding...

Jiangsu Hengrui Wave Third Chinese PD-1 to Market

Fast moving Chinese regulators wave third homegrown PD-1 to market Jiangsu Hengrui has secured an OK for its PD-1 drug, marking the fifth PD-1 approval in China and tilting the scale toward homegrown...

AstraZeneca and MSD’s Lynparza Doubled Progression-Free Survival in Pancreatic Cancer

AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced detailed results from the Phase III POLO trial at the 2019 American Societ...

Epizyme Submitted Application to FDA for Epithelioid Sarcoma Treatment

biotech-lab
Epizyme, Inc., a late-stage biopharmaceutical company developing novel epigenetic therapies, announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for a...

FDA Approves sNDA for XOSPATA®

Astellas Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) to update the U.S. product labeling for XOSPATA® (gilteritinib) to i...

J&J Published Data from Phase 3 DARZALEX® Study

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the publication of data from the randomized, open-label Phase 3 MAIA (MMY3008) study that showed DARZALEX® (daratumumab) plus le...

Celgene Received FDA Approval for REVLIMID

Celgene Corporation announced the U.S. Food and Drug Administration (FDA) approved REVLIMID® (lenalidomide) in combination with a rituximab product (R²) for the treatment of adult patients with previo...

Breakthrough Therapy Designation for LN-145

biotech-lab
Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, announced that the U.S. Food and Drug...

Array BioPharma Announced Colorectal Cancer Combo Treatment Met Primary Endpoints

cancer drugs
Array BioPharma Inc. announced positive results from the interim analysis of the Phase 3 BEACON CRC trial evaluating the combination of BRAFTOVI®(encorafenib), a BRAF inhibitor, MEKTOVI® (binimetinib)...

ImmunoGen Urged by FDA to Run Another Phase III Trial for Mirvetuximab Soravtansine

ImmunoGen, based in Waltham, Mass., announced that the U.S. Food and Drug Administration (FDA) recommended it run a new Phase III clinical trial of mirvetuximab soravtansine in high folate receptor (F...

Agios Pharma’s Tibsovo Showed Positive Results in Cholangiocarcinoma Study

biotech-lab
Agios Pharmaceuticals, headquartered in Cambridge, Mass., announced that its Tibsovo (ivosidenib) hit its primary endpoint in the Phase III ClarIDHy trial in patients with cholangiocarcinoma with an i...